Golimumab
Brand name: Simponi Aria
Rank #225 of 500 drugs by total cost
$59.9M
Total Cost
8,718
Total Claims
$59.9M
Total Cost
471
Prescribers
$6,867
Cost per Claim
161
Beneficiaries
9,631
30-Day Fills
$127K
Avg Cost/Provider
19
Avg Claims/Provider
About Golimumab
Golimumab (sold as Simponi Aria) was prescribed 8,718 times by 471 Medicare Part D providers in 2023, costing the program $59.9M. At $6,867 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 222 | Dextromethorphan Hbr/Quinidine (Nuedexta) | $60.7M | 60,863 |
| 223 | Interferon Beta-1a/Albumin (Rebif) | $60.7M | 5,917 |
| 224 | Sodium Zirconium Cyclosilicate (Lokelma) | $60.2M | 77,902 |
| 225 | Golimumab (Simponi Aria) | $59.9M | 8,718 |
| 226 | Olanzapine (Olanzapine) | $59.4M | 1,444,781 |
| 227 | Metoprolol Tartrate (Metoprolol Tartrate) | $59.4M | 6,859,124 |
| 228 | Omeprazole/Sodium Bicarbonate (Omeprazole-Sodium Bicarbonate) | $58.6M | 27,976 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology